Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

Clinical and Diagnostic Laboratory Immunology

Volumn 10, Issue 4, 2003, Pages 514-519

  Wernette, Catherine M ^a   Frasch, Carl E ^b   Madore, Dace ^c   Carlone, George ^d   Goldblatt, David ^e   Plikaytis, Brian ^d   Benjamin, William ^a   Quataert, Sally A ^c   Hildreth, Steve ^c   Sikkema, Daniel J ^c   Käyhty, Helena ^f   Jonsdottir, Ingileif ^g   Nahm, Moon H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c PFIZER INC   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMO23; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; PNULMUNE;

ANTIBODY SCREENING; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; LABORATORY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INDICATORS AND REAGENTS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; RADIOIMMUNOASSAY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; WORLD HEALTH ORGANIZATION;

EID: 12444319919     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.10.4.514-519.2003     Document Type: Short Survey

References (72)

1. Advisory Committee on Immunization Practices. 1989. Pneumococcal polysaccharide vaccine. Morb. Mortal. Wkly. Rep. 38:64-68, 73-76.
2. Anderson, P., R. Insel, S. Porcelli, and J. Ward. 1987. Immunochemical variables affecting radioantigen-biding assays of antibody to Haemophilus influenzae type b capsular polysaccharide in children's' sera. J. Infect. Dis. 156:582-590.
3. Anttila, M., M. Voutilainen, V. Jantti, J. Eskola, and H. Käyhty. 1999. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118:402-407.
4. Avery, O., and R. Dubos. 1931. The protective action of a specific enzyme against type III pneumococcus infection in mice. J. Exp. Med. 54:73-89.
5. Black, S., S. Shinfield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, and K. Edwards. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
6. Briles, D., J. Paton, E. Swiatlo, and M. Nahm. 2000. Pneumococcal vaccines, p. 244-250. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. ASM Press, Washington, D.C.
7. Chu, R., T. McCool, N. Greenspan, J. Schreiber, and C. Harding. 2000. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect. Immun. 68:1450-1456.
8. Cole, R. 1913. Treatment of pneumonia by means of specific serums. JAMA 61:663-666.
9. Concepcion, N., and C. Frasch. 1998. Evaluation of previously assigned antibody concentrations in pneumococcal polysaccharide reference serum 89SF by the method of cross-standardization. Clin. Diagn. Lab. Immunol. 5(2):199-204.
10. Concepcion, N., and C. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272.
11. Coughlin, R., A. White, C. Anderson, G. Carlone, D. Klein, and J. Treanor. 1998. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 16:1761-1767.
12. Fedson, D., and D. Musher. 1994. Pneumococcal vaccine, p. 517-564. In S. A. Plotkin and E. A. Mortimer (ed.), Vaccines, 2nd ed. The W. B. Saunders Co., Philadelphia, Pa.
13. Frasch, C., and N. Concepcion. 2000. Specificity of human antibodies reactive with pneumococcal C polysaccharide. Infect. Immun. 68:2333-2337.
14. Goidl, E., J. Cerny, G. Kelsoe, and D. Schulze. 1992. Aging and humoral immunity. Md. Med. J. 41:609-613.
15. Hausdorff, W., J. Bryant, P. Paradiso, and G. Siber. 2000. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use. Part I. Clin. Infect. Dis. 30:100-121.
16. Hausdorff, W., J. Bryant, P. Paradiso, and G. Siber. 2000. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use. Part II. Clin. Infect. Dis. 30:122-140.
17. Henrichsen, J. 1995. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol. 33:2759-2762.
18. Hetherington, S., and A. Rutkowski. 1990. Antibody affinity in infants after immunization with conjugated capsular polysaccharide from Haemophilus influenzae type b. J. Infect. Dis. 162:1185-1188.
19. Hosea, S., C. Burch, E. Brown, R. Berg, and M. Frank. 1981. Impaired immune response of splenectomized patients to polyvalent pneumococcal vaccine. Lancet i:804-807.
20. Jakobsen, H., S. Bjarnarson, F. Del Giudice, M. Moreau, C. Siegrist, and I. Jonsdottir. 2002. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect. Immun. 70:1443-1452.
21. Jakobsen, H., E. Saeland, S. Gizurarson, D. Schulz, and I. Jonsdottir. 1999. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect. Immun. 67:4128-4133.
22. Jakobsen, H., D. Schluz, M. Pizza, R. Rappuoli, and I. Jonsdottir, 1999. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun. 67:5892-5897.
23. Janoff, E., R. Breiman, C. Daley, and P. Hopewood. 1992. Pneumococcal disease during HIV infection: epidemiologic, clinical and immunologic perspectives. Ann. Intern. Med. 117:314-324.
24. Jefferis, R., C. Reimer, F. Skvaril, F. De Lange, N. Ling, J. Lowe, M. Walker, D. Phillips, C. Aloisio, T. Wells, J. Vaerman, C. Magnusson, H. Kubagawa, M. Cooper, F. Vartdal, B. Vandvik, J. Haaijman, O. Mäkelä, A. Sarnesto, Z. Lando, J. Gergely, E. Rajnavolgyi, G. Laszlo, J. Radl, and G. Molinaro. 1985. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. Immunol. Lett. 10:223-252.
25. Jodar, L., J. Butler, G. Carlone, R. Dagan, C. Frasch, D. Goldblatt, H. Käyhty, K. Klugman, B. Plikaytis, G. Siber, R. Kohberger, I. Chang, and T. Cherian. Serological criteria for evaluation and licensure of pneumococcal conjugate vaccine formulations for use in infants. Vaccine, in press.
26. Johnson, S., L. Rubin, S. Romero-Steiner, J. Dykes, L. Pais, A. Rizvi, E. Ades, and G. Carlone. 1999. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae. J. Infect. Dis. 180:133-140.
27. Jonsson, S., G. Vidarsson, H. Valdimarsson, G. Schiffman, R. Schneerson, and I. Jonsdottir. 2002. Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine. Eur. Respir. J. 20:813-818.
28. Katz, A., S. Landesman, and G. Schiffman. 1984. A comparison of antibody concentration measured by mouse protection assay and radioimmunoassay in sera from patients at high risk of developing pneumococcal disease. Mol. Immunol. 21:1061-1065.
29. Koskela, M. 1987. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr. Infect. Dis. J. 6:519-526.
30. Lee, L., C. Lee, and C. Frasch. 2002. Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests. Crit. Rev. Microbiol. 28:27-41.
31. Lottenbach, R., C. Mink, S. Barenkamp, E. Anderson, S. Homan, and D. Powers. 1999. Age-associated differences in immunoglobulin G1(IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect. Immun. 67:4935-4938.
32. Madore, D., N. Strong, and S. Quataert. 1999. Validation and standardization of serologic methods for evaluation of clinical immune response to vaccines, p. 43-76. In L. Paoletti and P. McInnes (ed.), Vaccines: from concept to clinic. CRC Press, Inc., New York, N.Y.
33. Matsuura, E., Y. Igarashi, T. Yasuda, D. Triplett, and T. Koike. 1994. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179:457-462.
34. Mbelle, N., R. Huebner, A. Wasas, A. Kimura, I. Chang, and K. Klugman. 1999. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180:1171-1176.
35. Musher, D., A. Chapman, A. Goree, S. Jonsson, D. Briles, and R. Baughn. 1986. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154:245-256.
36. Musher, D., D. Watson, and R. Baughn. 1990. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection? J. Infect. Dis. 161:736-740.
37. Nabors, G., P. Braun, D. Herrmann, M. Heise, D. Pyle, S. Gravenstein, M. Schilling, M. Ferguson, S. Hollingshead, D. Briles, and R. Becker. 2000. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18:1743-1754.
38. Nahm, M., J. Olander, and M. Magyarlaki. 1997. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J. Infect. Dis. 176:698-703.
39. Nahm, M., F. Siber, and J. Olander. 1996. A modified Farr assay is more specific than ELISA for measuring antibodies to S. pneumoniae capsular polysaccharides. J. Infect. Dis. 173:113-118.
40. Nuorti, J., J. Butler, M. Farley, L. Harrison, A. McGeer, M. Kolczak, and M. Breiman. 2000. Cigarette smoking and invasive pneumococcal disease. N. Engl. J. Med. 342:681-689.
41. Plikaytis, B., D. Goldblatt, C. Frasch, C. Blondeau, M. Bybel, G. Giebink, I. Jonsdottir, H. Käyhty, H. Konradsen, D. Madore, M. Nahm, C. Schulman, P. Holder, T. Lezhava, C. Elie, and G. Carlone. 2000. An analytical model applied to a multicenter pneumococcal ELISA study. J. Clin. Microbiol. 38:2043-2050.
42. Plikaytis, B., P. Holder, L. Pais, S. Maslanka, L. Gheesling, and G. Carlone. 1994. Determination of parallelism and nonparallelism in bioassay dilution curves. J. Clin. Microbiol. 32:2441-2447.
43. Plikaytis, B., S. Turner, L. Gheesling, and G. Carlone. 1991. Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 29:1439-1446.
44. Powers, D., E. Anderson, K. Lottenbach, and C. Mink. 1996. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J. Infect. Dis. 173:1014-1018.
45. Puumalainen, T., M. Zeta-Capeding, H. Käyhty, M. Lucero, K. Auranen, O. Leroy, and H. Nohynek. 2002. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr. Infect. Dis. J. 21:309-314.
46. Quataert, S. A., C. S. Kirch, L. J. Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
47. Redd, S., G. Rutherford, M. Sande, A. Lifson, W. Hadley, R. Facklam, and J. Spika. 1990. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J. Infect. Dis. 162:1012-1017.
48. Rennels, M., K. Edwards, H. Keyserling, K. Reisinger, D. Hogerman, D. Madore, I. Chang, P. Paradiso, F. Malinoski, and A. Kimura. 1998. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101:604-611.
49. Robbins, J., R. Austrian, C. Lee, S. Rastogi, G. Schiffman, J. Henrichsen, P. Makela, C. Broome, R. Facklam, R. Tiesjema, and J. Parke, Jr. 1983. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis. 148:1136-1159.
50. Romero-Steiner, S., D. Libutti, L. Pais, J. Dykes, P. Anderson, J. Whitin, H. Keyserling, and G. Carlone. 1997. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin. Diagn. Lab. Immunol. 4:415-422.
51. Romero-Steiner, S., D. Musher, M. Cetron, L. Pais, J. Groover, A. Fiore, B. Plikaytis, and G. Carlone. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29:281-288.
52. Rubins, J., M. Alter, J. Loch, and E. Janoff. 1999. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect. Immun. 67:5979-5984.
53. Saeland, E., H. Jakobsen, G. Ingolfsdottir, S. Sigurdardottir, and I. Jonsdottir. 2001. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J. Infect. Dis. 183:253-260.
54. Saeland, E., F. Vidarsson, and I. Jonsdottir. 2000. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb. Pathog. 29:81-91.
55. Sarnaik, S., J. Kaplan, F. Schiffman, D. Bryla, J. Robbins, and R. Schneerson. 1990. Studies on Pneumococcus vaccine alone or mixed with DTP and on Pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia. Pediatr. Infect. Dis. J. 9:181-186.
56. Schiffman, G., R. Douglas, M. Bonner, M. Robbins, and R. Austrian. 1980. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J. Immunol. Methods 33:133-144.
57. Schlesinger, Y., and D. Granoff. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 267:1489-1494.
58. Shelly, M., H. Jacoby, G. Riley, B. Graves, M. Pichichero, and J. Treanor. 1997. Comparison of pneumococcal polysaccharide and CRM197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect. Immun. 65:242-247.
59. Shinefield, H., and S. Black. 2000. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr. Infect. Dis. J. 19:394-397.
60. Siber, G., C. Priehs, and D. Madore. 1989. Standardization of antibody assays for measuring the response to pneumococcal infection and immunization. Pediatr. Infect. Dis. J. 8:S84-S91.
61. Sorensen, U., J. Henrichsen, H. Chen, and S. Szu. 1990. Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods. Microb. Pathog. 8:325-334.
62. Stack, A., Kobzik, L., C. Thompson, G. Siber, and R. Saladino. 1998. Minimum protection serum concentrations of pneumococcal anti-capsular antibodies in infant rats. J. Infect. Dis. 177:986-990.
63. Sun, Y., Y. Hwang, and M. Nahm. 2001. Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B. Infect. Immun. 69:336-344.
64. Usinger, W., and A. Lucas. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:2366-2370.
65. Vaidya, H., D. Dietzler, and J. Ladenson. 1985. Inadequacy of traditional ELISA for screening hybridoma supernatants for murine monoclonal antibodies. Hybridoma 4:271-276.
66. Vernacchio, L., H. Bernstein, S. Pelton, C. Allen, K. MacDonald, J. Dunn, D. Duncan, G. Tsao, V. LaPosta, J. Eldridge, S. Laussucq, D. Ambrosino, and D. Molrine. 2002. Effect of monophosphoryl lipid A MPL on T-helper cells when administered as an adjuvant with pneumococcal-CRM(197) conjugate vaccine in healthy toddlers. Vaccine 20:3658-3667.
67. Vidarsson, G., S. Sigurdardottir, T. Gudnason, S. Kjartansson, K. Kristinsson, G. Ingolfsdottir, S. Jonsson, H. Valdimarsson, G. Schiffman, R. Schneerson, and I. Jonsdottir. 1998. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect. Immun. 66:2866-2870.
68. Vitharsson, G., I. Jonsdottir, S. Jonsson, and H. Valdimarsson. 1994. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 170:592-599.
69. Ward, J., D. Greenberg, P. Anderson, K. Burkart, P. Christenson, L. Gordon, H. Käyhty, J. Kuo, and P. Vella. 1988. Variable quantitation of Haemophilus influenzae type b anticapsular antibody by radioantigen binding assay. J. Clin. Microbiol. 26:72-78.
70. Wuorimaa, T., R. Dagan, M. Vakevainen, G. Bailleux, T. Haikala, M. Yaich, J. Eskola, and H. Käyhty. 2001. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184:1211-1215.
71. Yu, X., Y. Sun, C. Frasch, N. Concepcion, and M. Nahm. 1999. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin. Diagn. Lab. Immunol. 6:519-524.
72. Zangwill, K., C. Vadheim, A. Vannier, L. Hemenway, D. Greenberg, and J. Ward. 1996. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J. Infect. Dis. 174:752-759.